Shirt a Phobia

Sample Page

iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family.[1] It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT).[1] The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor.[1] It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake.[1] The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001).[1] The chemical synthesis of iPALT has been described.[1] Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002).[1] 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use.[2][3][4][5] iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.[1]

See also

References

  1. ^ a b c d e f g h US 20240277665A1, Daley PF, Cozzi NV, Callaway WB, ”Asymmetric allyl tryptamines”, issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc. 
  2. ^ “Delving into the Latest Updates on Tryptamine(ASRI) with Synapse”. Synapse. 16 April 2025. Retrieved 19 April 2025.
  3. ^ Goldstein L (10 July 2023). “Pioneering Psychedelics Scientist Alexander “Sasha” Shulgin’s Legacy Lives On Via New Compounds And Research”. Benzinga. Retrieved 19 April 2025.
  4. ^ Busby M (2 November 2023). “The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown”. DoubleBlind Mag. Retrieved 19 April 2025.
  5. ^ Busby M (30 March 2025). “What Happens When You Inherit 500 Psychedelic Compounds?”. DoubleBlind Mag. Retrieved 19 April 2025.